Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 21, 2025, discloses the vesting of Deferred Annual Bonus Plan (DABP) awards granted in 2022 to Persons Discharging Managerial Responsibilities (PDMRs). The awards, which included nil-cost options over Ordinary Shares and restricted awards over American Depositary Shares (ADSs), completed their three-year restricted period on February 17 and 18, 2025. The filing details the subsequent sale of shares by these executives to meet tax liabilities.
Key Financial Metrics
This filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of executive compensation transactions. The following market prices were noted for the transaction dates:
- Ordinary Shares Closing Price (Feb 17, 2025): £14.195
- ADS Closing Price (Feb 18, 2025): $36.61
Material Changes and Transactions
The filing reports a series of transactions involving the vesting of awards and the sale of shares to cover tax obligations. No material changes to the company's business operations or financial position are reported. The specific transactions include:
- Emma Walmsley (CEO): Vested 81,703 Ordinary Shares; sold 38,459 shares at £14.1818.
- Dr. Hal Barron (Non-Executive Director): Vested 45,690 ADSs; sold 24,623 ADSs at $36.6355.
- Diana Conrad (Chief People Officer): Vested 12,825 Ordinary Shares; sold 6,883 shares at £14.2070.
- James Ford (SVP, Legal): Vested 15,792 Ordinary Shares; sold 7,441 shares at £14.2001.
- Sally Jackson (SVP, Communications): Vested 7,371 Ordinary Shares; sold 3,477 shares at £14.2000.
- Luke Miels (Chief Commercial Officer): Vested 26,851 Ordinary Shares; sold 618 shares at £14.1950.
- Shobie Ramakrishnan (Chief Digital Officer): Vested 2,786 ADSs; sold 1,502 ADSs at $36.6355.
- David Redfern (President, Corporate Development): Vested 17,805 Ordinary Shares; sold 8,390 shares at £14.1906.
- Regis Simard (President, Global Supply Chain): Vested 16,172 Ordinary Shares; sold 7,620 shares at £14.1954.
- Phil Thomson (President, Global Affairs): Vested 11,220 Ordinary Shares; sold 5,287 shares at £14.1929.
- Deborah Waterhouse (CEO, ViiV Healthcare): Vested 11,841 Ordinary Shares; sold 5,580 shares at £14.1985.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transactions were executed in accordance with the shareholder-approved 2017 Remuneration Policy and the DABP rules. All sales were conducted on the London Stock Exchange (XLON) or New York Stock Exchange (XNYS) to satisfy tax liabilities arising from the vesting events.
Investor Verification Checklist
- Verify the total number of shares retained by each executive after the tax sales to assess net equity exposure.
- Confirm the alignment of these vesting events with the company's 2017 Remuneration Policy and performance metrics.
- Review the aggregate volume of shares sold against the company's total outstanding share count to assess dilution impact (if any).
- Check for any subsequent filings regarding the retention of shares by these PDMRs.